dihexa clinical trials status 2026 / Semax / Selank Aerosol Spray · Disguised Alpha Unlocking the Potential of Dihexa

Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation

So far this product is working I am excited to continue to see the results

Prevalent AHM use reflects prior drug exposure, which could influence treatment effects, whereas age is a fundamental determinant of treatment response and dementia risk

Common (1-10 in 100): headache, dizziness, nausea, feeling of warmth, diarrhea